AB SCIENCE SA (AB.PA) Stock Fundamental Analysis

EPA:AB • FR0010557264

1.326 EUR
0 (-0.3%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

Overall AB gets a fundamental rating of 1 out of 10. We evaluated AB against 55 industry peers in the Pharmaceuticals industry. AB may be in some trouble as it scores bad on both profitability and health. AB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AB had negative earnings in the past year.
  • In the past year AB has reported a negative cash flow from operations.
  • In the past 5 years AB always reported negative net income.
  • AB had negative operating cash flow in 4 of the past 5 years.
AB.PA Yearly Net Income VS EBIT VS OCF VS FCFAB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -40.25%, AB is doing worse than 83.64% of the companies in the same industry.
Industry RankSector Rank
ROA -40.25%
ROE N/A
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AB.PA Yearly ROA, ROE, ROICAB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

  • The Gross Margin of AB (90.75%) is better than 94.55% of its industry peers.
  • AB's Gross Margin has improved in the last couple of years.
  • AB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
AB.PA Yearly Profit, Operating, Gross MarginsAB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AB has been increased compared to 1 year ago.
  • Compared to 5 years ago, AB has more shares outstanding
  • Compared to 1 year ago, AB has a worse debt to assets ratio.
AB.PA Yearly Shares OutstandingAB.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AB.PA Yearly Total Debt VS Total AssetsAB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -19.88, we must say that AB is in the distress zone and has some risk of bankruptcy.
  • AB has a worse Altman-Z score (-19.88) than 85.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.88
ROIC/WACCN/A
WACC7.91%
AB.PA Yearly LT Debt VS Equity VS FCFAB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • A Current Ratio of 0.67 indicates that AB may have some problems paying its short term obligations.
  • With a Current ratio value of 0.67, AB is not doing good in the industry: 89.09% of the companies in the same industry are doing better.
  • AB has a Quick Ratio of 0.67. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of AB (0.67) is worse than 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.67
AB.PA Yearly Current Assets VS Current LiabilitesAB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.25%.
  • AB shows a decrease in Revenue. In the last year, the revenue decreased by -5.08%.
  • Measured over the past years, AB shows a decrease in Revenue. The Revenue has been decreasing by -7.36% on average per year.
EPS 1Y (TTM)-23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.33%
Revenue 1Y (TTM)-5.08%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-8.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.66% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, AB will show a decrease in Revenue. The Revenue will decrease by -4.65% on average per year.
EPS Next Y68.29%
EPS Next 2Y30.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.09%
Revenue Next 2Y-4.65%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AB.PA Yearly Revenue VS EstimatesAB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
AB.PA Yearly EPS VS EstimatesAB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AB.PA Price Earnings VS Forward Price EarningsAB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AB.PA Per share dataAB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AB's earnings are expected to grow with 30.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.66%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AB SCIENCE SA

EPA:AB (2/13/2026, 7:00:00 PM)

1.326

0 (-0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-30
Earnings (Next)05-11
Inst Owners0.12%
Inst Owner ChangeN/A
Ins Owners30.8%
Ins Owner ChangeN/A
Market Cap87.75M
Revenue(TTM)1.03M
Net Income(TTM)-8.54M
Analysts84.44
Price Target3.79 (185.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.06%
PT rev (3m)-12.06%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 85.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.02
BVpS-0.41
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.75%
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-51.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.74%
GM growth 5Y5.64%
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.43%
Cap/Sales 19.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.67
Altman-Z -19.88
F-Score3
WACC7.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)39.08%
Cap/Sales(5y)35.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.33%
EPS Next Y68.29%
EPS Next 2Y30.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.08%
Revenue growth 3Y-12.62%
Revenue growth 5Y-7.36%
Sales Q2Q%-8.04%
Revenue Next Year-9.09%
Revenue Next 2Y-4.65%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.21%
OCF growth 3YN/A
OCF growth 5YN/A

AB SCIENCE SA / AB.PA FAQ

What is the fundamental rating for AB stock?

ChartMill assigns a fundamental rating of 1 / 10 to AB.PA.


What is the valuation status for AB stock?

ChartMill assigns a valuation rating of 1 / 10 to AB SCIENCE SA (AB.PA). This can be considered as Overvalued.


What is the profitability of AB stock?

AB SCIENCE SA (AB.PA) has a profitability rating of 1 / 10.


How financially healthy is AB SCIENCE SA?

The financial health rating of AB SCIENCE SA (AB.PA) is 0 / 10.


What is the expected EPS growth for AB SCIENCE SA (AB.PA) stock?

The Earnings per Share (EPS) of AB SCIENCE SA (AB.PA) is expected to grow by 68.29% in the next year.